Biochemotherapy with interleukin-2, interferon-α and 5-fluorouracil for the treatment of patients with metastatic renal cancer;Immunchemotherapie des metastasierten Nierenzell-karzinoms mit Interleukin-2, Interferon-α und 5-Fluorouracil

Urologe - Ausgabe A

Volumn 36, Issue 1, 1997, Pages 45-49

  Hofmockel, G ^a   Theiss M ^a   Gruss A ^a   Langer, W ^a   Frohmuller H ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

chemotherapy; immunotherapy; metastasis; renal cell carcinoma

Indexed keywords

ALPHA INTERFERON; FLUOROURACIL; INTERLEUKIN 2; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; FEMALE; FEVER; HUMAN; IMMUNOTHERAPY; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CANCER; LEUKOPENIA; MALE; METASTASIS; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME; WEIGHT REDUCTION; ADJUVANT CHEMOTHERAPY; CANCER STAGING; DOSE RESPONSE; DRUG ADMINISTRATION; FOLLOW UP; KIDNEY CARCINOMA; KIDNEY TUMOR; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; INTERFERON-ALPHA; INTERLEUKIN-2; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING;

EID: 0031055806     PISSN: 03402592     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001200050065     Document Type: Article

References (25)

1. Atkins MB, Sparano J, Fisher R et al. (1993) Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alpha-2b in advanced renal cell carcinoma. J Clin Oncol 11: 661-670
2. Atzpodien J, Shimazaki C, Wisniewski D et al. (1988) Interleukin-2 and Interferon-a in der adoptiven Immuntherapie des Plasmozytoms: Ein experimentelles Modell. In: Lutz D, Heinz R, Novotny H, Stacher A (eds) Leukämien und Lymphome. Urban & Schwarzenberg, München Wien Baltimore, S 211-212
3. Atzpodien J, Körfer A, Franks CR, Poliwoda H, Kirchner H (1990) Hometherapy with recombinant interleukin-2 and interferon-alpha-2b in advanced human malignancies. Lancet 335: 1509-1512
4. Atzpodien J, Kirchner H, Lopez-Hänninen E, Deckert M, Fenner M, Poliwoda H (1993) Interleukin-2 in combination with interferon-α and 5-fluorouracil for metastatic renal cell cancer. Eur J Cancer 29 [Suppl 5]: 6-8
5. Atzpodien J, Kirchner H, Lopez-Hämnissen E et al. (1995) Randomized and non-randomized outpatient studies of interlcukin-2, interferon-alpha and chemotherapy in metastatic renal carcinoma. Oncology 18 [Suppl 2]: 107
6. Atzpodien J, Lopez-Hänninen E, Kirchner H et al. (1995) Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma. J Clin Oncol 13: 497-501
7. Bono AV (1986) Steroid hormones and hormonal treatment in renal cell carcinoma. In: deKernion JB, Pavone-Macaluso M (eds) Tumors of the kidney. Williams & Wilkins, Baltimore, pp 205-227
8. Brunda MJ, Bellantoni D, Sulich V (1987) In vivo anti-tumor activity of combinations of interferon alpha and interleukin-2 in a murine model. Correlation of efficacy with the induction of cells resembling natural killer cells. Int J Cancer 40: 3948-3953
9. deKernion JB (1983) Treatment of advanced renal cell carcinoma-traditional methods and innovative approaches. J Urol 130: 2-7
10. deRiese W, Allhoff E, Kirchner H, Stief CG, Atzpodien J, Maschek H, Jonas U (1991) Complete spontaneous regression in metastatic renal cell carcinoma - an update and review. World J Urol 9: 184-191
11. Hofmockel G, Wirth MP, Heimbach D, Frohmüller HGW (1993) Ergebnisse der niedrig dosierten Interferon-Gamma-Therapie beim metastasierten Nierenzellkarzinom. Urologe A 32: 290-294
12. Hofmockel G, Theiß M, Bussen D, Wirth MP, Frohmüller HGW (1994) Behandlung des fortgeschrittenen Nierenzellkarzinoms mit subkutan appliziertem Interleukin-2 und Interferon-α. Urologe A 33: 434-439
13. Huland E, Heinzer H, Huland H (1994) Inhaled interleukin-2 in combination with low-dose systemic interleukin-2 and interferon alpha in patients with pulmonary metastatic renal-cell carcinoma: effectiveness and toxicity of mainly local treatment. J Cancer Res Clin Oncol 120: 221-228
14. Jones M, Philip T, Palmer P, von der Maase H, Vinke J, Elson P, Franks CR, Selby P (1993) The impact of interleukin-2 on survival in renal cancer: A multivariate analysis. Cancer Biother 8:275-288
15. Lissoni P, Barni S, Ardizzoia A, Scardino E, Cardellini P, Della-Bitta R, Tancini G (1993) A randomized study of low-dose interleukin-2 subcutaneous immunotherapy versus interleukin-2 plus interferon-alpha as first line therapy for metastatic renal cell carcinoma. Tumori 79: 397-400
16. Lopez-Hänninen E, Kirchner H, Atzpodien J (1996) Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients. J Urol 155: 19-25
17. Palmer PA, Vinke J, Philip T et al. (1992) Prognostic factors of survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2. Ann Oncol 3: 475-480
18. Rackley R, Novick A, Klein E, Bukowski R, McLain D, Goldfarb D (1994) The impact of adjuvant nephrectomy on multimodality treatment of metastatic renal cell carcinoma. J Urol 152: 1399-1403
19. Reiter Z, Ozes ON, Blatt LM, Taylor MW (1992) A dual antitumor effect of a combination of interferon-α, interleukin-2 and 5-fluorouracil on natural killer cell-mediated cytotoxicity. Clin Immun Immunopathol 62: 103-111
20. Rosenberg SA, Lotze MT, Yang JC et al. (1989) Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer. J Clin Oncol 7:1863-1874
21. Rosenberg SA, Yang JC, Topalian SL et al. (1994) Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin-2. JAMA 271: 907-913
22. Vuoristo M, Jantunen I, Pyrhönen S, Muhonen T, Kellokumpu-Lehtinen P (1994) A combination of subcutaneous recombinant interleukin-2 and recombinant interferon-α in the treatment of advanced renal cell carcinoma or melanoma. Eur J Cancer 30: 530-532
23. Wadler S, Schwartz EL (1990) Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review. Cancer Res 50: 3473-3486
24. West WH, Tauer KW, Yannelli JR et al. (1989) Multiple cycles of constant infusion recombinant interleukin-2 in adoptive cellular therapy of metastatic renal carcinoma. Mol Biother 1: 268-274
25. Wirth MP (1993) Immunotherapy for metastatic renal cell carcinoma. Urol Clin North Am 20: 283-295